NCT00637884View on ClinicalTrials.gov

A Single-Center, Randomized, Double-Blind, Placebo-Controlled, Two-Way Crossover Study Designed to Evaluate the Efficacy of Fexofenadine HCl 180 mg for Preventing and Controlling Cat Allergy Symptoms

PHASE4CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

November 30, 2003

Study Completion Date

February 29, 2004

Conditions
Cat Induced Allergic Rhinitis
Interventions
DRUG

Fexofenadine HCl

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY